Author:
Mostafid A. Hugh,Palou Redorta Joan,Sylvester Richard,Witjes J. Alfred
Reference10 articles.
1. Mould at Toronto plant may affect supplies of cancer drug. Canadian Press Web site. http://www.cbc.ca/news/canada/toronto/mould-at-toronto-plant-may-affect-supplies-of-cancer-drug-1.1282152. Accessed November 4, 2014.
2. BCG immunotherapy for bladder cancer--the effects of substrain differences;Gan;Nat Rev Urol,2013
3. Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance;Oddens;Eur Urol,2013
4. Approach for consideration to address shortage of bacillus Calmette-Guérin (BCG). Bladder Cancer Canada Web site. https://bladdercancercanada.org/images/uploads/pdf/Approach_to_Address_BCG_Shortage__Sept_11,_2014_.pdf. Accessed November 4, 2014
5. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer;Malmström;Eur Urol,2009
Cited by
65 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献